ICI’s clinical impact on cancer therapy has been so far very relevant: in the past 10 years, eight immune checkpoint blockers against CTLA-4, PD-1, or PD-L1 have been approved for clinical use in more than 85 oncology indications [1,2]. This evidence concerns the gene CTLA4 and cancer.